Traynor Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Traynor Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,000	Closed	-$1.95K	–	367
2025 Q3	$1.95K	Buy	+15,000	New	+$2.06K	﹤0.01%	362

Other funds holding ADAP

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Traynor Capital Management's ADAP Position: Q4 2025 in Review

Traynor Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 15,000 shares — an estimated $1.95K sold.

Traynor Capital Management first reported a position in ADAP in Q3 2025 and held it in 1 quarter. The position peaked at $1.95K in Q3 2025. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

Traynor Capital Management reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
Traynor Capital Management sold 15,000 Adaptimmune Therapeutics shares in Q4 2025, an estimated $1.95K.
Traynor Capital Management first reported a position in Adaptimmune Therapeutics in Q3 2025 and held it in 1 quarter.
Traynor Capital Management's Adaptimmune Therapeutics position peaked at $1.95K in Q3 2025.
10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Traynor Capital Management's 13F filing for Q4 2025, filed 12 Jan 2026.